• 21 June, 2025

Lupin receives USFDA approval for Cinacalcet Tablets

July 05, 2019 | Friday | News

It is the generic version of Sensipar Tablets

Lupin has announced that it has received approval for its Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg from the United States Food and Drug Administration.

Lupin’s Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg, is the generic version of Sensipar Tablets, 30 mg, 60 mg, and 90 mg, of Amgen Inc. It is indicated in the treatment of:

  • secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis
  • hypercalcemia in adult patients with Parathyroid Carcinoma
  • severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy

Cinacalcet Tablets, 30 mg, 60 mg, and 90 mg, had annual sales of approximately USD 1527 million in the US.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up
New User? Create Account

Trending Topics

Most Read

Survey Box

Is India’s Integrated DigiTech targeting Affordable Healthcare Access?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy